Advertisement
Canada markets open in 4 hours 37 minutes
  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CAD/USD

    0.7310
    -0.0011 (-0.15%)
     
  • CRUDE OIL

    78.78
    +0.30 (+0.38%)
     
  • Bitcoin CAD

    88,008.86
    -1,450.52 (-1.62%)
     
  • CMC Crypto 200

    1,330.64
    -34.49 (-2.53%)
     
  • GOLD FUTURES

    2,324.40
    -6.80 (-0.29%)
     
  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • NASDAQ futures

    18,182.75
    -12.75 (-0.07%)
     
  • VOLATILITY

    13.54
    +0.05 (+0.37%)
     
  • FTSE

    8,305.30
    +91.81 (+1.12%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6790
    -0.0002 (-0.03%)
     

Shareholders in Else Nutrition Holdings (TSE:BABY) are in the red if they invested a year ago

Else Nutrition Holdings Inc. (TSE:BABY) shareholders should be happy to see the share price up 14% in the last quarter. But in truth the last year hasn't been good for the share price. After all, the share price is down 45% in the last year, significantly under-performing the market.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

Check out our latest analysis for Else Nutrition Holdings

Else Nutrition Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

ADVERTISEMENT

In the last year Else Nutrition Holdings saw its revenue grow by 122%. That's well above most other pre-profit companies. Given the revenue growth, the share price drop of 45% seems quite harsh. Our sympathies to shareholders who are now underwater. Prima facie, revenue growth like that should be a good thing, so it's worth checking whether losses have stabilized. Our brains have evolved to think in linear fashion, so there's value in learning to recognize exponential growth. We are, in some ways, simply the wisest of the monkeys.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

Given that the market gained 7.8% in the last year, Else Nutrition Holdings shareholders might be miffed that they lost 45%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. It's great to see a nice little 14% rebound in the last three months. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 5 warning signs for Else Nutrition Holdings (of which 2 shouldn't be ignored!) you should know about.

But note: Else Nutrition Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on CA exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.